Hydronephrosis associated with ureteral metastasis of prostate cancer: A rare case report

Introduction

The ureter is a rare location of metastasis, irrespective of the primary cancer lesion (1). The most common malignant tumors metastasizing to the ureter are breast cancer and stomach cancer, whereas colon, cervix and rectum cancers also metastasize to the ureter with an appreciable frequency (1). However, ureteral metastasis from prostate cancer is extremely rare (2). The present case study reported such an incidence of a patient presenting hydronephrosis secondary to ureteral metastasis of prostate cancer.

Case report

A 63-year-old man presented with asymptomatic right hydronephrosis, detected by ultrasound in our department. Computed tomography urography (CTU; SOMATOM® Definition Flash, Siemens Healthcare, Erlangen, Germany) demonstrated right hydronephrosis, a dilated middle-upper ureter secondary to thickening of the distal ureter (Fig. 1), and benign prostatic hyperplasia (BPH). The result of the urine analysis was negative for hematuria. The serum prostate specific antigen (PSA) concentration was 111.400 ng/ml. A digital rectal examination revealed an enlarged and stony hard prostate gland, and subsequent prostate needle biopsy revealed prostate adenocarcinoma, with a Gleason score of 4+5=9. Renal dynamic scintigraphy revealed that the glomerular filtration rate was only 10.56 ml/min on the right side. Fluorescence in situ hybridization of the exfoliated cells in the urine did not reveal any evidence of malignancy.

Figure 1. CT images of the abdomen. (A) The CT revealed the right hydronephrosis and (B) a thickening of the right distal ureter (illustrated by the white arrow). CT, computed tomography.

On the basis of the results mentioned above, ureteroscopy was performed to determine whether the lesion of the distal ureter was transitional cell carcinoma (TCC) or metastasis of prostate cancer. The bladder wall and the right ureteral orifice were thickened and stiff. The ureteroscopy was hard to pass the stricture of the right distal ureter, thus rendering it impossible to obtain any biopsy result. Considering the higher degree of malignancy of TCC and the poor function of the right kidney, a nephroureterectomy was performed. Following surgical excision, the tissue was immediately placed in 4% formaldehyde solution prior to paraffin embedding. Serial sections (4 µm thickness) were obtained and stained with hematoxylin and eosin and 3,3′-diaminobenzidine for immunohistochemical staining. The histology results demonstrated a metastatic prostatic adenocarcinoma of the ureter. Immunohistochemical staining revealed that the PSA and P504 were positive. Combined androgen blockade therapy with bicalutamide (50 mg, once daily) and goserelin (3.6 mg, once a month) was then administered to the patient. At 3 months of follow-up, the patient's PSA levels had decreased to 0.322 ng/ml; at 6 months of follow-up, the PSA levels had further decreased to 0.136 ng/ml.

Discussion

The most common metastatic sites of prostate cancer are the lymph nodes and bone. The lung, bladder, liver and adrenal gland are other sites where metastasis occurs comparatively commonly. By contrast, ureteral metastasis of prostate cancer rarely occurs. In 1999, a total of 38 cases of ureteral metastases of prostate cancer were collected and reviewed by Haddad (2). Since then, several novel cases have been reported over the last 10 years (3–7). Among these cases, the most commonly reported symptom of ureteral metastasis is flank pain (15–50%) due to ureteral obstruction. Hematuria is not often identified. This may be due to the fact that the majority of ureteral tumors from distant primary sites are made by metastases beneath the mucosa, or they invade from surrounding tissues of the ureter. In the present case study, the patient had no subjective symptoms. CTU, retrograde pyelography and ureteroscopy may be useful for differential diagnosis in patients with prostate cancer who present with urinary obstruction symptoms.

The most common malignant tumors metastasizing to the ureter are breast cancer and stomach cancer (1), whereas colon, cervix, and rectum cancers also metastasize to the ureter relatively commonly. However, ureteral metastasis from prostate cancer is a rare occurrence. It often arises as a consequence of direct invasion of a prostate cancer or compression by lymphadenopathy. In the present case study, the patient's prostate cancer had most likely been caused by direct invasion, since the bladder wall and the right ureteral orifice were thickened and stiffened, as observed during ureteroscopy.

Hydronephrosis associated with ureteral stenosis/obstruction may be an early indicator of when the ureter is involved in prostatic cancer metastasis. Benign lesions, such as BPH and stones, should be taken into consideration first of all for differential diagnosis. In the present case, the possibility of metastatic prostate cancer would have been considered when evidence arose which indicated a malignant origin. However, the ureteroscopy proved hard to pass the stricture of the distal ureter, and biopsy results were not obtainable. Considering the higher degree of malignancy of TCC and the poor function of the right kidney, a nephroureterectomy was performed. A pathological examination revealed metastatic prostate adenocarcinoma.

In conclusion, the present case study details an unusual first presentation of prostate cancer without subjective symptoms. Metastatic lesions to the ureter due to prostate cancer occur very infrequently. Prostate cancer should be considered in the differential diagnosis of elderly men with lesions in the ureter, where a malignant origin is suspected. CTU, retrograde pyelography and ureteroscopy may be useful for differential diagnosis.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (no. 81101937).

References